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A 66-year-old man was treated with platinum-based induc-tion chemotherapy (three cycles) followed by thoracic
radiotherapy for stage IIIB non-small cell lung cancer. Be-
cause of the extent of the disease, high-dose thoracic radio-
therapy was not feasible, and 36 Gy/3 Gy fractions on the
originally involved areas, with a boost of 12 Gy/3 Gy to the
region of residual uptake on positron emission tomography
scan after chemotherapy was given.
Six months after the initial therapy, the patient experi-
enced anorexia, thoracic pain and cough, based on a local
relapse. Administration of the first cycle of second-line pem-
etrexed (after standard premedication) was complicated 5
days later by a painful, itchy, CTC-NCI grade 2, rash on the
thoracic wall (Figure 1). The skin was red, warm, painful, and
edematous in an area matching the radiation portal (Figure 2).
A skin biopsy revealed a moderate perivascular infiltrate of
lymphocytes and eosinophils of the superficial dermis and to
a lesser extent of the deeper dermis, compatible with urticar-
ial drug reaction (Figure 3). Treatment with local corticoste-
roids resulted in complete resolution of the rash within 3 days
and the further pemetrexed administration was uneventful.
DISCUSSION
We describe a case of radiation recall dermatitis (RRD)
occurring during second-line pemetrexed in a patient treated
6 months after the end of thoracic radiotherapy.
RRD is a rare, well known, but poorly understood
phenomenon. After administration of some antineoplastic
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FIGURE 1. Clinical image of radiation recall dermatitis in a
previously irradiated field.
FIGURE 2. Radiation field with the delivered dose of 36 Gy
in 3 Gy fractions on the originally involved areas, with a
boost of 12 Gy/3Gy to the region of residual uptake on
positron emission tomography scan after chemotherapy.
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drugs, there is “recalling” of an effect similar to an acute
radiation reaction in a previously irradiated field and it is
characterized by a mixed nonspecific inflammatory skin re-
action. Many hypotheses such as epithelial stem cell inade-
quacy, local vascular changes, epithelial stem cell sensitivity,
or idiosyncratic drug hypersensitivity reaction have been
proposed to explain RRD.1
RRD usually occurs at first exposure to the responsible
drug and should be differentiated from radiosensitization.
There is little literature evidence on the incidence of RRD,
and most information is on the use of doxorubicin.1 Factors
increasing the risk of development of RRD are a higher dose
of radiotherapy, a shorter time interval between radiotherapy
and chemotherapy administration, and the specific dose-
timing combinations used. Although in one report the median
interval between radiotherapy and chemotherapy was re-
ported to be 39.5 days,2 the time needed between radiother-
apy an chemotherapy to avoid RRD is largely unknown.
Usually, patients are not rechallenged with the drug, but in
cases of further exposure, the reaction is often milder than the
initial presentation. When the drug is stopped, skin reactions
usually resolve within a few days. The role of steroids or
antihistamines in the resolution remain unclear.
To our knowledge, reports of RRD after administration
of pemetrexed are very rare. One case was described in a patient
with mesothelioma 19 days after radiation therapy (21 Gy/7 Gy
fractions) on the thoracoscopy and drainage orifices.3 Given the
short interval, pemetrexed could also have been acting as a
radiosensitizing agent some weeks after the radiotherapy. In
contrast to our patient, one other report mentioned unsuccess-
ful rechallenge with pemetrexed.4
As the use of pemetrexed for second line therapy in
non-small cell lung cancer—also after chemoradiation—is
increasing, it is important to recognize the pattern of RRD
induced by pemetrexed. If there are no good therapeutic
alternatives in a certain clinical situation, careful rechallenge
may be warranted.
REFERENCES
1. Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized
but neglected phenomenon. Cancer Treat Rev 2005;31:555–570.
2. Camidge R, Price A. Characterizing the phenomenon of radiation recall
dermatitis. Radiother Oncol 2001;59:237–245.
3. Hureaux J, Le GY, Tuchais C, Savary L, Urban T. Radiation recall
dermatitis with pemetrexed. Lung Cancer 2005;50:255–258.
4. Barlesi F, Tummino C, Tasei AM, Astoul P. Unsuccessful rechallenge
with pemetrexed after a previous radiation recall dermatitis. Lung
Cancer 2006;54:423–425.
FIGURE 3. Skin biopsy reveals a perivascular infiltrate of
lymphocytes (arrow head) and many eosinophils (arrow) in
the dermis, the epidermis is normal.
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